N/A
N=5,696
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Kenya
Malaria · Febrile Illness
Bottom Line
View on ClinicalTrials.gov: NCT04428307 ↗Enrolled (actual)
5,696
Serious AEs
—
Results posted
Feb 2024
Primary outcome: Primary: ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases — 313; 250; 339 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Conditional artemisinin combination therapy subsidy (Other); Testing incentive (Other)
- Age
- Pediatric, Adult, Older Adult · 1+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- Aug 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases |
313; 250; 339 | — |
| SECONDARY Use of Malaria Rapid Diagnostic Test |
819; 804; 813 | — |
| SECONDARY Adherence to the RDT (Rapid Diagnostic Test) Result Among All Those Tested in the Shop |
558; 595; 591 | — |
| SECONDARY Appropriate Case Management |
558; 595; 591 | — |
| SECONDARY ACT (Artemisinin Combination Therapy) Use Among Untested Clients |
523; 542; 601 | — |
Summary
Highly subsidized first-line antimalarials (artemisinin combination therapy or ACT) are available over the counter in the private retail sector in most malaria-endemic countries. Overconsumption of ACTs purchased over the counter is rampant due to their low price, high perceived efficacy, and absence of diagnostic tools to guide drug use. The ultimate goal of the proposed work is to improve antimalarial stewardship in the retail sector, which is responsible for distributing the majority of antimalarials in sub-Saharan Africa. Through a combination of diagnosis and treatment subsidies and provider-directed incentives, this approach will align provider and customer incentives with appropriate case management and thereby improve health outcomes.
The main objective of this study (Aim 2) is to test two key interventions in a random sample of private medicine retail outlets in Kenya. This will be a cluster-randomized controlled trial where the cluster is a private retail outlet that stocks and sells WHO quality-assured ACTs. This three-arm study will test 1) a consumer-directed intervention in the form of a diagnosis-dependent ACT subsidy, 2) both a provider-directed incentive for testing and a client-directed intervention in combination against 3) a comparison arm. Outlets in all three arms will offer malaria diagnostic testing to customers who wish to purchase one. Information for the primary and secondary outcomes will be collected during exit interviews with eligible customers. The primary outcome will be the proportion of ACTs sold to customers with a positive diagnostic test. The main secondary outcome will be the proportion of suspected malaria cases presenting to the retail outlet that are tested. Other secondary outcomes include adherence to the RDT result amongst those tested (defined as taking a quality-assured ACT following a positive test and refraining from taking an ACT following a negative test) and appropriate case management for all suspected malaria cases (proportion tested and adhered among all suspected cases).
Eligibility Criteria
All clients attending a participating outlet on the day selected for exit interviews will be eligible to be screened for inclusion into the interview sample.
Inclusion Criteria
- Participants with fever, or history of fever in the last 48 hours, or suspects they may have malaria
- Individual with malaria-like illness must be present at recruitment
- Older than one year of age
Exclusion Criteria
- Any individual with signs of severe illness requiring immediate referral
- Individuals who have taken an antimalarial in the last seven days, including for the current illness
- Patients <18 years without a parent or legal guardian present
Data sourced from ClinicalTrials.gov (NCT04428307). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.